Topic Listing for ACADIA Pharmaceuticals

Able Contents Ac-262271
Ac-262271 Treatment Glaucoma Acadia
Acadia Development Eyecare Compounds Acadia Forward-looking Statements
Acadia Harmaceuticals Acadia Letterhead
Acadia Patent Rights Acadia Patents
Acadia Patents Product Acadia Pharmaceuticals
Acadia Pharmaceuticals Announces Financing Acadia Pharmaceuticals Announces Partnership Sepracor
Acadia Pharmaceuticals Announces Pricing Public Stock Offering Acadia Pharmaceuticals Inc
Acadia Retains Rights Rest World Accept Draw Down
Acceptance Premises Lessees Work Improvements Accountants Pricewaterhousecoopers Llp Express Opinion Respect Audited Financial
Accredited Investor Sepracor Such Term Defined Rule 501 Accrued Expenses
Acknowledgement Risk Acp-103
Acp-103 Adjunctive Therapy Schizophrenia Acp-103 Co-therapy Schizophrenia
Acp-103 Pet Polysomnography Clinical Study Acp-103 Phase Pet Polysomnography Clinical Studies
Acp-103 Sleep Maintenance Insomnia Acp-103 Treatment Parkinsons Disease Psychosis
Acp-103 Treatment Sleep Maintenance Insomnia Acp-103 Treatment-induced Dysfunctions Parkinsons Disease
Acp-104 Acp-104 Stand-alone Treatment Schizophrenia
Acp-104 Therapy Schizophrenia Acp-104 Treatment Schizophrenia
Acp-104 Treatment Schizophrenia Providing Potential Cognitive Benefits Acp-105
Acp-105 Treatment Endocrine Indications Acp-106
Acp-106 Neuropsychiatry Sleep Indications Serotonin Preclinical Program Active Public Market Common Stock Value Thereof Determined
Additional Extension Programs Additional Legal Compliance
Additional License Grant Acadia Adjudication Material Breach
Adopted Pursuant 302 Sarbanes-oxley Act 2002 Adoption Statement Financial Accounting Standards 123
Adp Indication Adverse Securities Credit Market Conditions Reduced Capitalization Significantly
Aggregate Option Exercises Last Year-end Values Agn-xx
Allergan Allowance Additional
Alzheimers Disease Psychosis Alzheimers Disease Psychosis Adp
Am-831 Amendment
Amendment Continuation Prior Plan Transfer Funds Other Qualified Amendment Execution
Amendment Lease Amendment Termination
Amendments Anti-takeover Provisions Charter Documents Delaware Law Make Acquisition
Appraisers Set Base Rent Assignment
Assignment Form Assignment Option
Assignment Right Atification Election Ndependent Egistered Ublic Ccounting Irm
Atification Election Ndependent Uditors Audit Committee
Available Available Http Iracadia-pharmcom
Aventis Ayment Ecords Udits
Background Balance Sheet Components
Base Figure Base Rent
Base Rent Payable Base Rent Tenant Improvement Allowance Other Provisions
Basis Presentation Beneficial Owner Shares Registered Name Broker Bank
Beneficial Owner Shares Registered Name Broker Bank Other Beneficial Ownership Reporting Compliance
Between Each Dose Placebo Not Significant Biovail
Biovail Corporation Bls Patents
Broker Representation Builds Specialty Cns Pipeline
Business Financial Business Other
Business Other Highlights Calculation Surcharge
Cannabinoid Cb1 Preclinical Program Capitalized Terms Used Herein Not Otherwise Defined Meanings
Cash Equivalents Caution Regarding Forward-looking Information Safe Harbor Statement
Ceff Not Available Elect Make Draw Down Require Ceo Compensation
Certain Related-person Transactions Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Change Vote After Submitting Proxy
Changes Internal Control Over Financial Reporting Changes Stock Option Accounting Treatment Adversely Affect Results
Chemical-genomics Discovery Approach Chemistry-based Discovery Technologies
Chronic Pain Claims Relating Improper Handling Storage Disposal Biological Hazardous
Classes Directors Clinical Pipeline
Clinical Programs Clinical Trial Design
Clinical Trial Results Code Ethics
Collaboration Agreement Sepracor Collaboration Agreement Sepracor Inc
Collaboration Agreements Collaboration License Agreement
Collaboration License Agreements Collaborative Neuropathic Pain Program
Collaborative Research Licensing Agreements Commercialization
Commercialization Product Commitments
Commitments Contingencies Committed Equity Financing Facility
Committed Equity Financing Facility Ceff Not Available Elect Committed Equity Financing Facility Not Available Elect Make
Committees Common Stock Par Value 00001 Per Share
Common Stock Purchase Agreement Common Stock Reserved Future Issuance
Comparison 2003 2002 Comparison 2004 2003
Comparison 2005 2004 Comparison 2006 2005
Comparison 2007 2006 Comparison 2008 2007
Comparison 2009 2008 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Report Executive Compensation Directors
Compensation Philosophy Competition
Competitors Develop Market Products Effective Drug Candidates They Competitors Develop Market Products Effective Product Candidates They
Complete Tenants Share Compliance
Compliance Law Compounds
Comprehensive Income Loss Comprehensive Loss
Concentrations Risk Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Operations Conditions Closing
Conduct Development Activities Conference Call Scheduled Today 2009 830 Eastern Time
Conference Call Webcast Information Confidential Treatment Requested
Confidentiality Confidentiality Agreements Employees Others Not Adequately Prevent Disclosure
Confirmation Defined Terms Conflicts Arise Collaborators They Act Self Interests Adverse
Conflicts Government Consents Permits Consent Independent Registered Public Accounting Firm
Consolidated Financial Statements Consumers Sue Product Liability Result Substantial Liabilities Exceed
Controls Procedures Convertible Preferred Stock
Corporate Seal Corporation
Covenants Critical Accounting Policies Estimates
Current Ownership Acadia Other Shares Acquired Rights Provided Data Based Panss Using Intent Treat Population Last
Decision-making Development Committee Definitions
Delays Suspensions Terminations Clinical Trials Result Increased Costs Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Principal Officers Election Appointment Depend Collaborations Parties Develop Commercialize Selected Drug Candidates
Depend Collaborations Parties Develop Commercialize Selected Product Candidates Description Executive Officer Annual Incentive Cash Compensation Program
Description Outside Director Compensation Program Development Activities
Development Activities Adp Development Committee
Development Funding Development Regulatory Activities
Development Status Diligence Obligations
Director Compensation Director Compensation 2006
Director Compensation 2007 Director Independence
Directors Directors Continuing Office Until 2006 Annual Meeting
Directors Continuing Office Until 2007 Annual Meeting Directors Continuing Office Until 2008 Annual Meeting
Directors Continuing Office Until 2009 Annual Meeting Directors Continuing Office Until 2010 Annual Meeting
Directors Continuing Office Until 2011 Annual Meeting Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disclosure Controls Procedures
Disease Market Overview Disposition Warrant Exercise Shares
Dispute Concerning Infringement Misappropriation Proprietary Rights Others Time Dispute Resolution Governing Law
Distribution Agreements Sublicenses Dividends
Documents Filed Part Report Documents Incorporated Reference
Draw Down Terms Drug Candidates Neuropathic Pain
Drug Candidates Not Gain Acceptance Among Physicians Patients Drug Development Programs
Drug Discovery Approach Drug Discovery Opportunities
Drug Discovery Platform Drug Discovery Platform Capabilities
Drug Discovery Platform Capabilities Overview Drugs Serious Life-threatening Illnesses
Earnings Loss Per Share Earthquake Damage Facilities Delay Research Development Efforts Adversely
Earthquake Fire Damage Facilities Delay Research Development Efforts Ecitals
Ection Eneficial Wnership Eporting Ompliance Eetings Inutes
Effect Change Control Stock Option Awards Effect Expiration Termination Option Period
Effect Termination Effect Termination Surviving Obligations
Efinitions Elements Executive Compensation
Employee Stock Purchase Plan Employees
Employers Copy Employment Severance Change Control Agreements
Eneral Rovisions Engage Acquisition Incur Variety Costs Never Realize Anticipated
Entry Material Definitive Agreement Eport Udit Ommittee Oard Irectors
Epresentations Arranties Epresentations Older
Equity Compensation Plan Information Er-beta Program
Erformance Easurement Omparison Erm Ermination
Ertain Elationships Elated Ransactions Esponsibilities Uties
Estimates Even Collaborators Successfully Complete Clinical Trials Drug Candidates
Even Collaborators Successfully Complete Clinical Trials Product Candidates Even Successfully Complete Clinical Trials Drug Candidates They
Exact Name Registrant Specified Charter Example
Examples Executive Compensation
Exercise Option Licensed Compound Other Forms Exhibits
Expansion Option Expansion Pipeline
Expect Net Losses Continue Least Several Unable Predict Expect Results Operations Fluctuate Make Difficult Predict Future
Expenses Extension Term
Face Financial Administrative Challenges Coordinating Operations European Activities Face Financial Administrative Challenges Opening New Chemistry Research
Fail Obtain Capital Necessary Fund Operations Unable Successfully Failure Appraisers Set Fair Market Value
Failure Exercise Rights Fair Value Financial Instruments
Fair Value Measurements Figure Composite Human Brains Demonstrating High 5-ht2a Receptor
Financial Results Financial Statements Exhibits
Financial Statements Supplementary Data Financing
Find Out Results Voting Annual Meeting Fixed Co-formulation Product Development Commercialization License
Fixing Record Dates Fluctuations Operating Results
Foreign Currency Risk Foreign Currency Translation
Form 10-k Form 10-k 2008
Form 10-q Form Draw Down Notice
Form Opinion Counsel Form Press Release
Form Press Releases Former Name Address Changed Since Last Report
Forward-looking Other Statements Forward-looking Statements
Gain Settlement Litigation General Administrative Expenses
General Provisions Glaucoma
Governing Law Governing Law Miscellaneous
Government Regulation Governmental Consents Permits
Grants Plan-based Awards Grants Plan-based Awards 2006
Grants Plan-based Awards 2007 Grants Plan-based Awards 2008
Greement Held 2005
Held 2006 Held 2007
Held 2008 Held 2009
Herefore Consideration Foregoing Covenants Premises Contained Amendment Parties Highlights
Hsr Act Shall Mean Hart-scott-rodino Antitrust Improvements 1976 In-service Withdrawals
Incidental Registration Income Taxes
Incur Increased Costs Result Recently Enacted Proposed Changes Incurred Expect Continue Incur Increased Costs Result Recently
Incurred Expect Continue Incur Significant Costs Result Laws Incurred Expect Continue Incur Significant Costs Result Recently
Ind Plan Shall Mean Written Development Conduct Preclinical Ind-track Development Preclinical Programs
Indemnification Indemnification Contribution
Indemnification Directors Executive Officers Other Employees Agents Independence Board Directors
Independence Board Directors Committees Index
Index Exhibits Information Regarding Committees Board Directors
Infringement Parties Initial Public Offering
Instructions Property Tax Clause Non-residential Premises Insurance
Intellectual Property Interest Expense
Interest Income Interest Rate Risk
Internal Control Over Financial Reporting Interpretation
Investment Contributions Investment Securities
Ipsen Patent Rights Iscellaneous
Ispute Esolution Ist Arties Ock Greements
Joint Development Committee Joint Inventions Shall Mean Conceived Simultaneously Reduced Practice
Joint Patents Joint Research Committee
Joint Research Committee Decision-making Joint Steering Committee Decision-making
Joint Steering Committee Formation Meetings Key Components Drug Discovery Platform
Lection Irectors Legal Proceedings
Legends Lessee Improvement Allowance
Lessee Improvements Amortization Rent Lessee Undertake Construction
Lessees Payment Costs Lessors Work
License License Agreement
License Agreements License Fees
License Grant Acadia License Grant Msk
License Number 902745460-000058 Version 601 Registered Wihlborgs Fastigheter License Option Collaboration Agreement
Licensed Compound Other Forms Licenses Manufacturing License Outside Territory
Lien Releases Limitations
Limited Proprietary Rights Drug Candidates Acp-104 Limit Ability Liquidity Capital Resources
List Subsidiaries Loans Officers
Long Lived Assets Long-lived Assets
Long-term Debt Management Broad Discretion Over Cash Not Effectively Adversely
Managements Report Internal Control Over Financial Reporting Manufacture Supply
Manufacturing Market Registrants Common Equity Related Stockholder Matters Issuer
Marketing Sales Distribution Material Adverse Effect Shall Meaning Set Forth
Material Not Soliciting Deemed Filed Sec Incorporated Reference Material Report Not Soliciting Deemed Filed Sec Incorporated
Meetings Meetings Board Directors
Meetings Board Directors Committee Member Attendance Meiji Seika Kaisha
Meiji Seika Kaisha Ltd Method Exercise Rights Represented Warrant Exercised Whole Part
Miscellaneous Most Advanced Clinical Products Trials Long Expensive Unpredictable
Most Advanced Drug Candidates Clinical Trials Long Expensive Most Advanced Product Candidates
Most Advanced Product Candidates Clinical Trials Long Expensive Msk Patents
Muscarinic Preclinical Program Muscarinic Program
Mutual Covenant Name Person Filing Proxy Statement Other Registrant
Ndemnification Need Increase Size Organization Encounter Difficulties Managing Growth
Need Transition Organization Connection Most Recent Restructuring Encounter Need Transition Organization Connection Restructuring Encounter Difficulties Managing
Net Income Loss Per Common Share Net Income Loss Per Share
Neuropathic Pain Nominating Corporate Governance Committee
Nominees Election Three-year Term Expiring 2008 Annual Meeting Nominees Election Three-year Term Expiring 2009 Annual Meeting
Nominees Election Three-year Term Expiring 2010 Annual Meeting Nominees Election Three-year Term Expiring 2011 Annual Meeting
Nominees Election Three-year Term Expiring 2012 Annual Meeting Nonqualified Deferred Compensation
Not Able Continue Fully Exploit Collaborations Outside Scientific Not Check Smaller Reporting
Not Continue Realize Expected Benefits Restructuring Announced 2008 Not Know Whether Drug Candidates Acp-104 Same Adverse
Not Know Whether Drug Discovery Platform Lead Development Not Realize Expected Benefits Restructuring Announced 2008 Operating
Not Realize Expected Benefits Restructuring Announced 2009 Operating Notes Consolidated Financial Statements
Notices Number Price Shares
Oard Irectors Ecommends Ote Lection Ach Ominee Amed Ode Usiness Onduct Thics
Off-balance Sheet Arrangements Offer Letters Employment Agreements
Officers Officers Certificate
Officers Directors Largest Stockholders Choose Act Together They Offices
Ompensation Irectors Omposition
Onfidentiality Ongoing Litigation Consume Management Financial Resources Adversely Affect
Onsultant Greement Open Door Policy Reporting Accounting Auditing Matters
Open-label Extension Study Acp-103 Option Exercises 2006
Option Exercises 2007 Option Exercises 2008
Option Exercises Stock Vested Option Period
Options Organization
Organization Nature Operations Ote Avor Ach Amed Ominee
Other Bls Termination Rights Other Development Activities Pdp
Other Development Programs Other Drug Candidates
Other Events Other Product Candidates
Other Regulatory Requirements Other Securities Corporation
Oting Nstructions Ouseholding Roxy Aterials
Outstanding Equity Awards Year-end Ovenants Ompany
Overview Ownership Intellectual Property
Page Parking Lot
Parkinsons Disease Parkinsons Disease Psychosis
Parkinsons Disease Psychosis Pdp Part
Part Financial Information Part Other Information
Participant Loans Participants Accounts
Participation Parties Agreed Follows Reduction Rent Conjunction Customary Maintenance
Party Licenses Patent Applications Pharmaceutical Biotechnology Companies Involve Highly Complex
Paying Proxy Solicitation Payment Currency Conversion
Payments Payments Books Records
Payments Termination Pcap Preclinical Program
Pcap Program Pen Oor Olicy Eporting Ccounting Uditing Atters
Perform Such Other Duties Specifically Assigned Parties Development Pimavanerin Treatment Parkinsons Disease Psychosis
Pimavanserin Pimavanserin Adjunctive Therapy Schizophrenia
Pimavanserin Co-therapy Schizophrenia Pimavanserin Sleep Maintenance Insomnia
Pimavanserin Treatment Alzheimers Disease Psychosis Pimavanserin Treatment Parkinsons Disease Psychosis
Pimavanserin Treatment Parkinsons Disease Psychosis Pdp Plan
Plan Administration Plan Name Acadia Pharmaceuticals 401 Trust
Post-employment Compensation Post-research Term Rights
Potential Payment Employment Arrangements Ppendix
Pre-approval Policies Procedures Pre-construction Requirements
Preamble Preclinical 5-ht2 Program
Preclinical Discovery Programs Preclinical Muscarinic Program
Preclinical Program Price Common Stock Declines Below 100 Per Share
Price Common Stock Remains Below 100 Per Share Price Common Stock Trades Below 100 Per Share
Principal Accountant Fees Services Principal Accounting Fees Services
Principles Consolidation Private Placement
Product Candidates Product Candidates Not Gain Acceptance Among Physicians Patients
Product Patents Programs
Properties Property Equipment
Proprietary Information Inventions Agreements Proprietary Receptor Assay Platforms
Proprietary Rights Shall Meaning Set Forth Prosecuting Defending Litigation Permitted Agreement Confidential Treatment Requested
Provision Loss Litigation Provision Loss Settlement Litigation
Public Announcements Public Offering
Public Offerings Public Stock Offering
Purchase Sale Common Stock Purchase Sale Securities
Purchasers Executing Delivering Agreement Reliance Exemption Securities Registration Purchasers Representations Warranties
Pursuant 302 Sarbanes-oxley Act 2002 Quantitative Qualitative Disclosures Market Risk
Quorum Voting R-sat Functional Assay Technologies
R-sat Other Functional Assay Technologies Reaffirmation
Receiving Materials Receiving Proxy Materials
Recent Accounting Pronouncement Recent Accounting Pronouncements
Recent Collaboration Accelerate Preclinical Pipeline Recent Developments
Recent Highlights Recently Issued Accounting Standards
Recitals Records Audits Adjustments
Registrants Telephone Number Including Area Code Registration Procedures
Registration Rights Registration Rights Agreement
Regulation Disclosure Regulatory Activities
Reinstatement Right Refusal Related-person Transactions Policy Procedures
Rely Parties Conduct Clinical Trials Perform Data Collection Rely Parties Coordinate Clinical Trials Perform Data Collection
Relying Third-party Manufacturers Result Delays Clinical Trials Product Remainder Page Intentionally Left Blank
Report Audit Committee Board Directors Report Independent Registered Public Accounting Firm
Representations Warranties Representations Warranties Covenants
Representations Warranties Covenants Investor Required Registrations
Research Commitment Research Development Costs
Research Development Expenses Restricted Stock Purchase Agreements
Restrictions Distributions Restructuring
Restructurings Results Operations
Results Operations Financial Condition Retained Rights Implied Licenses
Revenue Recognition Revenues
Reverse Stock Split Revised Offer
Right Benefits Right Refusal
Right Reinstatement Further Extension Rights Reserved Additional License Grant Acadia
Rights Termination Risk Factors
Risks Related Business Risks Related Common Stock
Risks Related Industry Royalties Sepracor Shall Pay Acadia Net Sales Each
Royalty Adjustment Royalty Payments
Sales Taxes Title Fees 422 Disbursement Allowance Additional San Diego 2008
Sarbanes-oxley Act 2002 Schedule
Schedule Purchasers Schizophrenia
Secondary Endpoint Measures Antipsychotic Efficacy Securities Exchange Act 1934
Securities Not Registered Securities Purchase Agreement
Securities Registered Pursuant Act Security Deposit
Security Ownership Certain Beneficial Owners Management Related Stockholder Segment Information
Segment Reporting Selected Muscarinic Compounds
Selected Quarterly Financial Data Selection Chosen Compounds
Sepracor Sepracor Announces Partnership Acadia
Sepracor Patents Serotonin Preclinical Program
Service Share Amount Shall Meaning Set Forth
Shares Stock Signage
Signature Page Follows Signature Pages Follow
Signatures Signatures Continue Next Page
Single-tenant Lease Net Site Plan Premises
Sleep Maintenance Insomnia Special Meetings
Special Provisions Stanley Medical Research Institute
Stock Option Activity Stock Option Grants Exercises
Stock Plans Stock Price Particularly Volatile Because Drug Discovery Development
Stock-based Compensation Stock-based Compensation Expenses
Stockholder Communications Board Directors Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Stockholders Equity
Stockholders Meetings Stockholders Sell Substantial Amounts Common Stock Market Price
Strategy Strengthening Acadias Business Development Organization
Subject Stringent Regulation Connection Marketing Products Derived Drug Subject Stringent Regulation Connection Marketing Products Derived Product
Subletting Assignment Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Summary Compensation Summary Compensation Table
Summary Compensation Table 2006 Summary Compensation Table 2007
Summary Significant Accounting Policies Superseding Annuity Distribution Provisions
Table Contents Tandstill Greement
Target-based Discovery Technologies Taxes
Telecommunications Equipment Tenure Duties Officers
Term Termination Termination
Termination Acadia Termination Lease 3931 Sorrento
Termination Option Ther Atters
Those Laws Shall Entitled Require Opinion Counsel Satisfactory Top-heavy Provisions
Transfers Treasurer Secretary
Treatment-induced Dysfunctions Parkinsons Disease Trial Design
Trial Results Trustees Copy
Unable Attract Retain Motivate Key Management Scientific Staff Unable Establish Sales Marketing Capabilities Enter Agreements Parties
United States Unless Contrary Direction Indicated Proxy Voted Each Nominee
Unregistered Sales Equity Securities Unresolved Staff Comments
Urchase Ale Ommon Tock Urpose Olicy
Uthority Vice President Chief Financial Officer Treasurer Secretary
Void After 2010 Volume Submitter Defined Contribution Plan
Vote Vote Annual Meeting
Votes Votes Counted
Votes Needed Approve Each Proposal Warrant
Warrants Warranty Authority
What Another Matter Properly Brought Before Meeting What Broker Non-votes
What Mean Receive Proxy Card What Proxy Materials Available Internet
What Quorum Requirement What Return Proxy Card Not Make Specific Choices
What Return Proxy Card Otherwise Vote Not Make What Voting
Whereas Withhold Authority Vote Individual Nominee Write Name Such
Xecutive Ompensation 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki